Information Provided By:
Fly News Breaks for July 20, 2016
JAZZ
Jul 20, 2016 | 08:21 EDT
Leerink analyst Jason Gerberry says the upcoming Inter Partes Review, or IPR, ruling on six patents covering Jazz Pharmaceuticals' Xyrem REMS has been a near-term overhang, but the generic challengers will need to overcome numerous other hurdles in order to launch a generic. Gerberry believes investor concerns into the REMS IPR ruling are overdone and recommends buying Jazz Pharmaceuticals' shares on any incremental IPR-related weakness. He reiterates an Outperform rating and $200 price target on the stock.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ